NASDAQ:LUMO Lumos Pharma (LUMO) Stock Price, News & Analysis $1.80 +0.26 (+16.88%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.48▼$1.9050-Day Range$1.45▼$2.6252-Week Range$1.37▼$4.55Volume107,070 shsAverage Volume39,660 shsMarket Capitalization$14.62 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Lumos Pharma alerts: Email Address Lumos Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside900.0% Upside$18.00 Price TargetShort InterestBearish6.97% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.27Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.15) to ($1.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.60 out of 5 starsMedical Sector711th out of 936 stocksPharmaceutical Preparations Industry331st out of 436 stocks 3.5 Analyst's Opinion Consensus RatingLumos Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLumos Pharma has received no research coverage in the past 90 days.Read more about Lumos Pharma's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted6.97% of the float of Lumos Pharma has been sold short.Short Interest Ratio / Days to CoverLumos Pharma has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.Change versus previous monthShort interest in Lumos Pharma has recently increased by 22.67%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLumos Pharma does not currently pay a dividend.Dividend GrowthLumos Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LUMO. Previous Next 1.8 News and Social Media Coverage News SentimentLumos Pharma has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Lumos Pharma this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for LUMO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lumos Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders25.40% of the stock of Lumos Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 33.99% of the stock of Lumos Pharma is held by institutions.Read more about Lumos Pharma's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Lumos Pharma are expected to grow in the coming year, from ($3.15) to ($1.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lumos Pharma is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lumos Pharma is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLumos Pharma has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Lumos Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Lumos Pharma Stock (NASDAQ:LUMO)Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.Read More LUMO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LUMO Stock News HeadlinesJuly 25 at 5:26 AM | americanbankingnews.comLumos Pharma (LUMO) Set to Announce Earnings on ThursdayJuly 23, 2024 | globenewswire.comLumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024July 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 21, 2024 | americanbankingnews.comFinancial Comparison: Lumos Pharma (NASDAQ:LUMO) vs. Xeris Biopharma (NASDAQ:XERS)July 19, 2024 | msn.comCrowdStrike CEO apologizes for tech outage, says systems should be recovering -NBCMay 21, 2024 | finanznachrichten.deLumos Pharma, Inc.: Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024May 20, 2024 | globenewswire.comLumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024May 16, 2024 | finance.yahoo.comLumos Pharma Inc (LUMO) Q1 2024 Earnings Call Transcript Highlights: Navigating Financial ...July 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 15, 2024 | finanznachrichten.deLumos Pharma, Inc.: Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial ResultsMay 14, 2024 | msn.comLUMO Stock Earnings: Lumos Pharma Misses EPS, Misses Revenue for Q1 2024May 14, 2024 | globenewswire.comLumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial ResultsMay 9, 2024 | globenewswire.comLumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024April 18, 2024 | globenewswire.comLumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical MeetingsMarch 21, 2024 | markets.businessinsider.comLumos Pharma’s LUM-201 Receives ‘Buy’ Rating on Strong Market Position and Promising Trial OutcomesMarch 20, 2024 | globenewswire.comLumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042March 11, 2024 | sg.news.yahoo.comBAT set to sell stake in India's ITC stake as soon as this week, Bloomberg reportsMarch 10, 2024 | finance.yahoo.comLumos Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsSee More Headlines Receive LUMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lumos Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/27/2024Next Earnings (Confirmed)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LUMO CUSIPN/A CIK1126234 Webwww.lumos-pharma.com Phone(512) 215-2630Fax515-296-3520Employees33Year FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$28.00 Low Stock Price Target$10.00 Potential Upside/Downside+900.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($4.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-34,030,000.00 Net Margins-2,434.69% Pretax Margin-2,436.59% Return on Equity-119.87% Return on Assets-85.93% Debt Debt-to-Equity RatioN/A Current Ratio6.24 Quick Ratio6.24 Sales & Book Value Annual Sales$1.53 million Price / Sales9.58 Cash FlowN/A Price / Cash FlowN/A Book Value$3.45 per share Price / Book0.52Miscellaneous Outstanding Shares8,116,000Free Float6,055,000Market Cap$14.61 million OptionableNot Optionable Beta0.72 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Richard J. Hawkins (Age 75)Founder, CEO & Chairman Comp: $854.35kDr. John C. McKew Ph.D. (Age 60)Chief Scientific Officer & President Comp: $860.38kMs. Lori D. Lawley CPA (Age 40)CFO & Principal Accounting Officer Comp: $538.23kMs. Lisa Wells MillerSenior Director of Investor RelationsMr. Bradley J. Powers J.D. (Age 45)Chief Compliance Officer & General Counsel Comp: $677.08kMr. Aaron Schuchart B.B.A. (Age 58)CPA, M.B.A., Chief Business Officer Dr. Pisit Pitukcheewanont FAAPM.D., Chief Medical OfficerMr. Eddie L. Varnado M.B.A.Corporate ControllerMore ExecutivesKey CompetitorsLexaria BioscienceNASDAQ:LEXXCarisma TherapeuticsNASDAQ:CARMKezar Life SciencesNASDAQ:KZRNabriva TherapeuticsNASDAQ:NBRVNextCureNASDAQ:NXTCView All CompetitorsInsiders & InstitutionsBlackstone Inc.Sold 247,928 shares on 5/16/2024Ownership: 0.968%John C MckewSold 2,214 sharesTotal: $6,132.78 ($2.77/share)John C MckewSold 438 sharesTotal: $1,327.14 ($3.03/share)John C MckewSold 3,407 sharesTotal: $10,936.47 ($3.21/share)View All Insider TransactionsView All Institutional Transactions LUMO Stock Analysis - Frequently Asked Questions How have LUMO shares performed this year? Lumos Pharma's stock was trading at $3.18 at the beginning of the year. Since then, LUMO stock has decreased by 43.4% and is now trading at $1.80. View the best growth stocks for 2024 here. How were Lumos Pharma's earnings last quarter? Lumos Pharma, Inc. (NASDAQ:LUMO) announced its quarterly earnings results on Tuesday, May, 14th. The company reported ($1.29) EPS for the quarter, missing analysts' consensus estimates of ($1.21) by $0.08. The firm had revenue of $0.17 million for the quarter, compared to analysts' expectations of $0.51 million. Lumos Pharma had a negative trailing twelve-month return on equity of 119.87% and a negative net margin of 2,434.69%. How do I buy shares of Lumos Pharma? Shares of LUMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Lumos Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lumos Pharma investors own include Advanced Micro Devices (AMD), Agilent Technologies (A), Air Lease (AL), Bionano Genomics (BNGO). This page (NASDAQ:LUMO) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lumos Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lumos Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
